Skip to main navigation

- Silverback - Corp Menu

About
Science & Technology
Pipeline
Careers
- Open Positions
Contact
Investors

News Releases

- Silverback - Investor Relations

Home
News & Events
Stock Information
- Stock Quote & Chart
- Analyst Coverage
Corporate Governance
Financials & Filings
- SEC Filings
- Quarterly Results
IR Resources
- Email Alerts
- Contact IR

Year

Silverback Therapeutics Announces Clinical Supply Agreement with Regeneron to Evaluate SBT6050 in Combination with Libtayo® (cemiplimab), initially in HER2-expressing Non-Small Cell Lung and Gastric Cancers

07-07-2021

Silverback Therapeutics to Participate in the Raymond James Human Health Innovation Conference

06-15-2021

Silverback Therapeutics to Participate in the Goldman Sachs 42nd Annual Global Healthcare Conference

06-01-2021

Silverback Therapeutics Reports First Quarter 2021 Financial Results

05-13-2021

Silverback Therapeutics to Present SBT6290 Preclinical Data at the AACR 2021 Annual Conference

04-08-2021

Silverback Therapeutics Reports Fourth Quarter and Full Year 2020 Financial Results and Recent Corporate Updates

03-29-2021

Silverback Therapeutics Announces the Appointment of Dr. Maria Koehler to its Board of Directors

03-15-2021

Silverback Therapeutics to Present at Upcoming Investor Conferences

02-16-2021

- Silverback - Investor Tools

Print Page
RSS Feeds
Email Alerts

- Silverback - Corp Menu

About
Science & Technology
Pipeline
Careers
- Open Positions
Contact
Investors

© Copyright 2021 - Silverback Therapeutics^®